CAS 1245626-05-4 AM6545 - Analytical Products / Alfa Chemistry

CAT	AP1245626054
CAS	1245626-05-4
MDL Number	MFCD19053178
Molecular Weight	556.46
InChI Key	XBHQLFVDGLPBCK-UHFFFAOYSA-N

Description	≥98% (HPLC)
Solubility	DMSO: >25 mg/mL
Assay	≥98% (HPLC)
Color	white to off-white
Form	powder
Size	5MG, 25MG
Storage Conditions	2-8°C

1

A Novel Peripherally Restricted Cannabinoid Receptor Antagonist, AM6545, Reduces Food Intake and Body Weight, but Does Not Cause Malaise, in Rodents

N L Cluny, V K Vemuri, A P Chambers, C L Limebeer, H Bedard, J T Wood, B Lutz, A Zimmer, L A Parker, A Makriyannis, K A Sharkey

Br J Pharmacol. 2010 Oct;161(3):629-42.

PMID: 20880401

1

Cannabinoid CB 1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity

Donovan A Argueta, Pedro A Perez, Alexandros Makriyannis, Nicholas V DiPatrizio

Front Physiol. 2019 Jun 11;10:704.

PMID: 31281260

1

Current Drug Targets in Obesity Pharmacotherapy - A Review

Sangeeta P Bhat, Arun Sharma

Curr Drug Targets. 2017;18(8):983-993.

PMID: 28245771

1

Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice

Haiming Ma, Guina Zhang, Chunrong Mou, Xiujuan Fu, Yadan Chen

Front Pharmacol. 2018 Mar 20;9:156.

PMID: 29615900

1

Reversal of Albuminuria by Combined AM6545 and Perindopril Therapy in Experimental Diabetic Nephropathy

F Barutta, S Bellini, R Mastrocola, R Gambino, F Piscitelli, V di Marzo, B Corbetta, V K Vemuri, A Makriyannis, L Annaratone, G Bruno, G Gruden

Br J Pharmacol. 2018 Dec;175(23):4371-4385.

PMID: 30184259

* Products or Services Interested: AM6545 (1245626-05-4)
* Your question
* Name
* Email
Verification Code